Literature DB >> 33812969

A quantitative approach to predicting lung deposition profiles of pharmaceutical powder aerosols.

Shadi Yaqoubi1, Hak-Kim Chan2, Ali Nokhodchi3, Siavoush Dastmalchi4, Ali Akbar Alizadeh4, Mohammad Barzegar-Jalali5, Khosro Adibkia6, Hamed Hamishehkar7.   

Abstract

Dry powder inhalers (DPI) are widely used systems for pulmonary delivery of therapeutics. The inhalation performance of DPIs is influenced by formulation features, inhaler device and inhalation pattern. The current review presents the affecting factors with great focus on powder characteristics which include particle size, shape, surface, density, hygroscopicity and crystallinity. The properties of a formulation are greatly influenced by a number of physicochemical factors of drug and added excipients. Since available particle engineering techniques result in particles with a set of modifications, it is difficult to distinguish the effect of an individual feature on powder deposition behavior. This necessitates developing a predictive model capable of describing all influential factors on dry powder inhaler delivery. Therefore, in the current study, a model was constructed to correlate the inhaler device properties, inhalation flow rate, particle characteristics and drug/excipient physicochemical properties with the resultant fine particle fraction. The r2 value of established correlation was 0.74 indicating 86% variability in FPF values is explained by the model with the mean absolute errors of 0.22 for the predicted values. The authors believe that this model is capable of predicting the lung deposition pattern of a formulation with an acceptable precision when the type of inhaler device, inhalation flow rate, physicochemical behavior of active and inactive ingredients and the particle characteristics of DPI formulations are considered.
Copyright © 2021 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  DPI; Dry powder inhaler; Particle engineering; Pulmonary drug delivery; Quantitative property-lung deposition relationship

Year:  2021        PMID: 33812969     DOI: 10.1016/j.ijpharm.2021.120568

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  2 in total

1.  Rational Development of a Carrier-Free Dry Powder Inhalation Formulation for Respiratory Viral Infections via Quality by Design: A Drug-Drug Cocrystal of Favipiravir and Theophylline.

Authors:  Si Nga Wong; Jingwen Weng; Ignatius Ip; Ruipeng Chen; Richard Lakerveld; Richard Telford; Nicholas Blagden; Ian J Scowen; Shing Fung Chow
Journal:  Pharmaceutics       Date:  2022-01-27       Impact factor: 6.321

2.  Investigation of potential substandard dry powder inhalers on EU and North African markets - evaluation of the delivered and fine particle doses.

Authors:  Yue Zhang; Philippe Hubert; Cédric Hubert
Journal:  J Drug Assess       Date:  2022-09-28
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.